Shock
Conditions
Keywords
Reducing shocks
Brief summary
Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number of shocks in primary prevention patients. In addition to shock therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE trial aims to prospectively study the effect of high detection rates, prolonged detection intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to first shock in primary prevention patients.
Interventions
DEVICEICD/ CRT-D
Cardiac device
Sponsors
Abbott Medical Devices
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary Prevention indication for ICD/ CRT-D
Exclusion criteria
* No prior documented history of spontaneous VT/VF
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is the rate of first shock | Average follow-up period is 530 days |
| The primary safety endpoint of this study is the rate of arrhythmic syncope | Average follow-up period is 530 days |
Countries
United States
Outcome results
None listed